REPL insider trading
NasdaqGS HealthcareReplimune Group, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Company website: www.replimune.com
REPL insider activity at a glance
FilingIQ has scored 381 insider transactions for REPL since Jul 24, 2018. The most recent filing in our index is dated Apr 2, 2026.
Across the full history, 7 open-market purchases
and 258 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on REPL insider trades is 60.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest REPL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding REPL
Frequently asked
- How many insider trades does FilingIQ track for REPL?
- FilingIQ tracks 381 Form 4 insider transactions for REPL (Replimune Group, Inc.), covering filings from Jul 24, 2018 onwards. 23 of those were filed in the last 90 days.
- Are REPL insiders net buyers or net sellers?
- Across the full Form 4 history for REPL, 7 transactions (2%) were open-market purchases and 258 (68%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does REPL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is REPL in?
- Replimune Group, Inc. (REPL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $701.87M.
Methodology & sources
Every REPL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.